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Objective: Bilateral adrenal metastases may cause adrenal insufﬁciency (AI) but it is unclear if screening for AI in
patients with bilateral adrenal metastases is justiﬁed, despite the potential for adrenal crises.
Method: A search using PubMed/Medline, ScienceDirect and Cochrane Reviews was performed to collect all
original research articles and all case reports from the past 50 years that describe AI in bilateral adrenal
metastases.
Results: Twenty studies were included with 6 original research articles, 13 case reports and one case series. The
quality was generally poor. The prevalence of AI was 3–8%. Of all cases of AI (n ¼ 25) the mean pooled baseline
cortisol was 318  237 nmol/L and stimulated 423  238 nmol/L. Hypotension was present in 69%, hyponatremia in 9% and hyperkalemia in 100%. Lung cancer was the cause in 35%, colorectal 20%, breast cancer 15%
and lymphoma 10%. The size of the adrenal metastases was 5.5  2.8 cm (left) and 5.5  3.1 cm (right),
respectively. There was no correlation between basal cortisol, stimulated cortisol concentration or ACTH with the
size of adrenal metastases. The median time to death was 5.0 months (IQR 0.6–6.5). However, two cases were
alive after 12–24 months.
Conclusion: The prevalence of AI in patients with bilateral adrenal metastases was low. Prognosis was very poor.
Due to the low prevalence of AI, screening is likely only indicated in patients with symptoms and signs suggestive
of hypocortisolism.

1. Introduction
Adrenal metastases in patients with malignancy are common, with
most data coming from autopsy studies. Between 28-42% of lung cancers
and 12–34% of breast cancers metastasize to the adrenals [1, 2], but
melanoma, renal, thyroid and colorectal cancer can do so as well [3]. The
adrenal glands have a rich sinusoidal supply which could be involved in
the pathogenesis [4]. Patients with adrenal metastases have a very poor
prognosis and in one study the 2 year survival was only 7% [5],
considerably lower than the highly lethal primary adrenocortical carcinoma [6].
Adrenal insufﬁciency (AI) was ﬁrst described in 1849 by Thomas

Addison who later described AI from adrenal metastases in 1855 [7].
Since then, the prevalence of AI with bilateral metastases has been unclear from the literature despite several studies and an increasing number
of case reports documenting the phenomenon.
AI can present with fatigue, weakness, weight loss, anorexia, nausea
or vomiting [8]. These symptoms are also commonly seen in metastatic
disease. Thus, a high degree of suspicion of AI is required when managing
advanced malignancies. However, despite the presence of bilateral adrenal metastases, adrenal function may be preserved until >90% of the
cortex is destroyed [9]. Signs of AI include hyperpigmentation from
raised adrenocorticotropin hormone (ACTH), hypotension, tachycardia
or fever [8]. Biochemically, primary AI may be manifest by
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quality assessment instrument was considered inappropriate, as they
were not developed to assess prevalence studies nor case reports/series.
All values for cortisol were documented in nmol/L (conversions made
if articles reported values in ug/dL) and for ACTH levels, values were
reported in pmol/L (conversions made for pg/mL).
Baseline serum/plasma cortisol at 8am was referred to as basal
cortisol and a serum/plasma cortisol level after administration of ACTH
(ACTH stimulation test) was referred to as stimulated cortisol.
Data from Table 3 of all collected cases of AI was used to assess certain
outcomes. An outcome was reported as a percent of how many of the
cases actually reported the outcome rather than total number of cases.

hyponatremia, hyperkalemia, hypoglycemia, hypercalcaemia and low
cortisol together with elevated ACTH. If AI is not diagnosed, adrenal
crisis may supervene, with a potentially fatal outcome [10].
For the diagnosis of primary AI, the ACTH stimulation test is currently
regarded as the 'gold standard' [8]. The Endocrine Society Guidelines
from 2016 recommend to use 250mcg of ACTH 1–24 (Cosyntropin®,
Synacthen®) to stimulate cortisol secretion [8]. It is recommended to use
peak rather than the change in cortisol [11]. Screening can be conducted
by determining a morning cortisol level; with a level <140 nmol/L
combined with a 2-fold or greater raised ACTH level being suggestive of
AI. The guidelines also recommend simultaneous measurement of plasma
renin and aldosterone to determine the presence of mineralocorticoid
deﬁciency [8].
The prevalence and characteristics of AI in bilateral adrenal metastases is not well-described. Thus, we have performed a systematic review
and meta-analysis to collate all relevant articles in order to provide a
summary on the topic.

2.1. Statistical analysis
Results were calculated after pooling the results of all studies. Results
are presented as the mean  standard deviation (SD) or median and
interquartile range (IQR) whichever was appropriate. Linear regression
was used to evaluate the correlation between the size of adrenal metastases and cortisol and ACTH concentrations, respectively. Statistical
signiﬁcance was deﬁned as P < 0.05. SigmaStat 3.0 for Windows (Systat
Software Inc., San Jose, California) was used for all analysis.

2. Method
The systematic review was carried out as recommended by the
PRISMA guidelines [12]. Systematic searches for eligible studies were
conducted using PubMed/MEDLINE, ScienceDirect and Cochrane Reviews up to June 26, 2018, using the following strategy: "adrenal
metastasis" AND ("adrenal failure" OR "adrenal insufﬁciency" OR
"Addison disease" OR "Addison's disease" OR hypocortisolism) and "adrenal metastases" AND ("adrenal failure" OR "adrenal insufﬁciency" OR
"Addison disease" OR "Addison's disease" OR hypocortisolism). In addition, the reference lists of the retrieved full-text studies were scanned to
identify other potentially relevant studies. One further original research
article known to us but not identiﬁed in the searches was added [13]. The
relevance of the articles was ﬁrst determined by reviewing the title, then
the abstract, and if necessary, full-text retrieval. Two authors (PHT and
HF) agreed on the included and excluded articles together with reference
to the criteria described below. Articles were excluded if they were review articles or not in English.
Original research articles from the systematic review of the literature
were used to collect cases of AI. To be included in the initial prevalence
calculations, the cases had to meet the following criteria: bilateral adrenal disease conﬁrmed by radiology or histology and having biochemical evidence of AI with an ACTH stimulation test. A second prevalence
calculation was performed to extend the number of studies included
which still required studies to demonstrate bilateral adrenal metastases
but could use alternative means for the diagnosis of AI.
Individual cases of AI were excluded if they did not meet this criteria
or if there was a nephrectomy, haemorrhage in an adrenal gland or
treatment that contributed to the AI.
The individual cases of AI from original research articles were
collated together with case reports to form a collection of cases of AI in
Table 1. To be included, case reports needed to have documented bilateral disease and an ACTH stimulation test performed. If an ACTH test was
not performed, then a baseline cortisol of <140 nmol/L was required to
be consistent with diagnostic criteria from 2016 Guidelines [8]. Data was
collected on age and sex of the patients, type of cancer, associated
symptoms and signs of AI, biochemical features (including baseline and
stimulated cortisol levels, and ACTH), size of metastases, treatment
regimen and mortality. Mortality was recorded as time to death from the
diagnosis of the AI.
Articles arising from the literature search that were not included but
contained data on adrenal function in malignancy or adrenal metastases
without necessarily having AI were collected and summarised to provide
some comparison of the collected data.
A quality assessment of the original research articles was incorporated with the strengths and limitations of each article noted in Table 2.
Assessment using, e.g., the Newcastle-Ottowa Scale (www.ohri.ca/progr
ams/clinical_epidemiology/oxford.asp), or any other standardized

3. Results
The searches identiﬁed 604 articles of which 24 were considered
eligible for inclusion in the systematic review (Fig. 1). Four case reports
did not meet inclusion criteria leaving 13 cases reports [14, 15, 16, 17,
18, 19, 20, 21, 22, 23, 24, 25, 26], one case series of four patients [27]
and six original research articles [13, 28, 29, 30, 31, 32]. Of these original research articles, four articles met criteria for the initial prevalence
calculation requiring bilateral disease and ACTH stimulation test to diagnose AI. Six articles (an additional two [13, 32]) were used for the
subsequent prevalence calculation which required less strict diagnosis of
AI. All articles included in prevalence calculations are included in Table 3
and detailed comments on the quality of these studies are documented in
Table 2. Two articles not meeting criteria had data included for comparison of cortisol between AI and non-AI groups as part of secondary
outcomes [9, 33].
Of the 19 case reports detected by the search, 13 met inclusion
criteria along with the case series, yielding a total of 17 individual cases
of AI. Along with eight individual cases collected from the original
research articles, there was a total of 25 cases of AI for data analysis
which are tabulated in Table 1.
3.1. Primary outcome
3.1.1. Prevalence of AI in bilateral adrenal metastases
A summary of the prevalence of AI in bilateral adrenal metastases is
shown in Table 3. When using strict inclusion criteria of documented
bilateral disease and an ACTH stimulation test for diagnosis, only four
studies could be included [28, 29, 30, 31] which date from 1981 to 2000
giving a small sample size of 85. The prevalence of AI was 7/85 (8%)
using this criteria. If excluding Redman et al. [30] since all 5 cases had a
basal cortisol level of >300 nmol/L yet failed to mount an appropriate
response to ACTH stimulation, the prevalence would be only 2/70 (3%).
To expand the sample size, an additional two studies [13, 32] could be
included yet they did not document an ACTH stimulation test as part of
diagnostic criteria. This extended the date of included studies to 2016
and gave a sample size of 264. The prevalence of AI was then 16/264
(6.1%).
We have further described the studies below in chronological order of
publication.
Cedermark et al [28] in 1981 documented seven patients with histology proven unilateral or bilateral adrenal metastases and evaluated
their adrenal function. This was done with an ACTH stimulation test, of
which the detailed criteria is not documented. Four patients had bulky
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Cancer/Histology

Low
BP

Post.
low BP

Low
Na

High
K

Cortisol nmol/L
(ug/dL)

ACTH pmol/L
(pg/mL)

Peak cortisol
after ACTH

Diagnosis

Largest size on CT
(cm) left/right

Treatment and follow-up

Overt adrenal insufﬁciency
Crisci et al [14]
69M

Colorectal

N

Y

-

-

ACTH stimulation test

-

43M

Lung ac

Y

Y

Y

Y

-

Cortisol and ACTH

Imaoka et al [16]

82M

Colorectal

N

-

N

Y

43M

Colorectal

Y

-

Y

Y

ACTH stimulation test

Gul et al [36]

47F

Gastric ac

N

Y

Y

Y

499 nmol/L
(18.1ug/dL)
386 nmol/L
(14.0ug/dL)
-

ACTH stimulation test

Mor et al [17]

69M

Y

-

Y

Y

-

Cortisol and ACTH

Noguchi et al [20]

78M

Lung signet ring
cell ac
Small cell lung

Y

-

Y

Y

ACTH-stimulation test

Bausewein et al [21]

75F

Breast

Y

-

Y

Y

ACTH-stimulation test

-

Srinivasan et al [22]

71M

Melanoma

Y

-

Y

-

77.2 nmol/L
(2.8ug/dL)
157.2 nmol/L
(5.7ug/dL)
-

12L
12R
2.5L
1.9R
7L
9R
4.7L
3.8R
5L
5R
-

TX with GC and MC. SX
improved. Alive 12 months.
TX with GC and MC.
Mortality - n/a
TX with GC. Died 5 months
later (unrelated to AI).
TX with GC. Died 8 months
later.
TX with GC. Mortality - n/a

Faulhaber et al [19]

63 pmol/L
(290 pg/mL)
<2.2 pmol/L
(<10 pg/mL)
6.6 pmol/L (28
pg/mL)
114 pmol/L
(520 pg/mL)
30.8 pmol/L
(140 pg/dL)
137.7 pmol/L
(626 pg/mL)
55.8 pmol/L
(254 pg/mL)
329 pmol/L
(1499 pg/mL)
-

-

Cosentino et al [15],*

220nmol (8ug/
dL)
19 nmol/L
(0.7ug/dL)
215nmol
(7.8ug/dL)
408 nmol/L
(14.8ug/dL)
275nmol
(10ug/dL)
28nmol
(1.03ug/dL)
115 nmol/L
(4.2ug/dL)
148nmol
(5.4ug/dL)
-

ACTH-stimulation test

Goffman et al [23]

48M

Renal ca

Y

Y

Y

Y

-

74M

Lymphoma

-

Y

Y

-

-

675 nmol/L
(24.5 ng/L)
-

ACTH-stimulation test

Schnitzer et al [24]
Van den
Heiligenberg et al
[25]
Yeo et al [26]

78M

Non-hodgkin
lymphoma

N

-

-

-

504 nmol/L
(18.3ug/dL)
22 nmol/L
(0.8ug/dL)
-

9.6L
7.4R
-

-

-

ACTH-stimulation test

78F

Breast

Y

-

-

-

-

-

Lung ac

Y

Y

Y

Y

Breast

Y

N

Y

Y

65M

Small cell lung

Y

-

Y

Y

80.3 pmol/L
(365 pg/mL)
-

48hr ACTH infusion

70M

Large cell lung

N

-

Y

Y

51M

Lung

-

-

-

-

ACTH-stimulation test

8L
8R
3.5L
9R
-

56M

Undifferentiated

-

-

-

-

ACTH-stimulation test

-

62M

Colon

-

-

-

-

182 nmol/L
(6.6ug/dL)
510 nmol/L
(18.5ug/dL)
292 nmol/L
(10.6ug/dL)
331 nmol/L
(12ug/dL)
259 nmol/L
(9.4ug/dL)
-

ACTH -stimulation test
40IU BD for 48 hrs
ACTH- stimulation test

-

75F

235 nmol/L
(8.5ug/dL)
248 nmol/L
(9ug/dL)
231 nmol/L
(8.4ug/dL)
400 nmol/L
(14.5ug/dL)
513 nmol/L
(18.6ug/dL)
358 nmol/L
(13ug/dL)
303 nmol/L
(11ug/dL)
-

ACTH-stimulation test

52M

265 nmol/L
(9.6ug/dL)
-

ACTH-stimulation test

-

-

-

-

-

-

-

ACTH-stimulation test

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

5L
5R
2.5L
2.5R
4L
3R
-

-

-

-

-

-

-

303 nmol/L
(11ug/dL)
745 nmol/L
(27ug/dL)
469 nmol/L
(17ug/dL)
993 nmol/L
(36ug/dL)
386 nmol/L
(14ug/dL)

-

55 pmol/L
(252 pg/mL)
-

331 nmol/L
(12ug/dL)
800 nmol/L
(29ug/dL)
524 nmol/L
(19ug/dL)
1020 nmol/L
(37ug/dL)
441 nmol/L
(16ug/dL)

ACTH-stimulation test

ACTH-stimulation test

ACTH-stimulation test

ACTH-stimulation test
ACTH-stimulation test
ACTH-stimulation test
ACTH-stimulation test

4L
4R
5L
5R

-

3.5L
1.5R

TX with GC and MC. SX
resolved. Alive at 1 month
TX with GC. Died 4 months.
TX with GC and MC. SX
resolved. Mortality - n/a
TX with GC. SX resolved.
Died 6 months later.
TX with GC. Died 3 days
later.
TX with GC. Died within 7
days.
TX with GC. SX improved.
Died 3 weeks later.
TX with GC. SX improved.
Died 1 year later
TX with GC. Died 6 months
later.
TX with GC and MC. SX
improved. Alive at 2 years.
TX with GC. Mortality - n/a
TX with GC. SX improved.
Mortality - n/a
Responded to GC. Mortality n/a
Responded to GC. Mortality n/a
Responded to GC and MC.
Mortality - n/a
-

Units Cortisol nmol/L (mg/dL); Units ACTH pmol/L (pg/mL); BP ¼ blood pressure; Post. low BP ¼ postural low blood pressure, i.e., orthostatic hypotensiont; Low Na ¼ hyponatremia; High K ¼ hyperkalemia; Y ¼ yes; N ¼
no; ' - ' ¼ not available; GC ¼ glucocorticoids; ac ¼ adenocarcinoma; MC ¼ mineralocorticoids; SX ¼ symptoms; TX ¼ treatment; n/a ¼ not available.
*
Cosentino et al. [15] - features of primary and secondary AI.
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Sheeler et al [27]
Patient 1
Sheeler et al [27]
Patient 2
Sheeler et al [27]
Patient 3
Sheeler et al [27]
Patient 4
Seidenwurm et al
[29] Patient 1
Seidenwurm et al
[29] Patient 3
Seidenwurm et al
[29] Patient 4
Redman et al [30]
Patient 1
Redman et al [30]
Patient 2
Redman et al [30]
Patient 3
Redman et al [30]
Patient 4
Redman et al [30]
Patient 5

Age
Sex
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All published cases of bilateral adrenal metastasis and adrenal insufﬁciency.
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cortisol for patients with and without AI and noted no signiﬁcant difference (656 nmol/L versus 582 nmol/L, respectively). However, they
noted a signiﬁcant difference between the mean increase in cortisol with
ACTH stimulation between AI and non-AI groups (increase by 35 nmol/L
versus 480 nmol/L, respectively).
Lutz et al [31] similarly compared adrenal function amongst patients
with malignancy where they performed a cross sectional study of 28
patients of whom none had AI on ACTH stimulation testing. There were
seven normal controls, 11 patients with no metastases, eight with unilateral metastases and nine with bilateral metastases. Compared to controls (baseline cortisol 307.4  33.2 nmol/L) the presence of cancer
without metastases increased baseline cortisol to 477.5  64.9 nmol/L,
to 440.4  53.5 nmol/L with unilateral metastases and to 637.6  92.1
nmol/L for bilateral metastases. Similarly, for stimulated cortisol levels
after ACTH administration there was a signiﬁcant rise in levels with
increasing degree of malignancy. Compared to controls (stimulated
cortisol 794.6  41.2 nmol/L) the presence of cancer without metastases
increased levels to 939.7  99.2 nmol/L; the presence of unilateral metastases increased levels to 990.8  92.9 nmol/L; and bilateral metastases
resulted in stimulated cortisol levels of 1151.4  155.5 nmol/L.
Cedermark et al [28] recorded baseline and stimulated cortisol values
for their four patients with bilateral metastases yet without AI. There was
a mean baseline cortisol of 862.5 nmol/L and a mean stimulated cortisol
1137.5 nmol/L. The mean increase in cortisol from baseline was 225
nmol/L.
Additional studies that did not meet inclusion criteria for the systematic review but revealed additional data on adrenal function in malignancy were those of Cedermark et al [9] and Ross et al [33].
Cedermark et al [9] had a second study published in year 1981 that
reviewed patients with cancer (non-lung cancer) that did not have adrenal metastases and evaluated their adrenal function via a cortisol and
an ACTH stimulation test. They divided their patients into two groups those that were in good physical condition (equivalent of Eastern
Cooperation Oncology Group (ECOG) score 0–2) and those that were in
poor physical condition (equivalent of ECOG 3 or 4). The ﬁrst group (n ¼
24 patients), those in good physical condition, had a baseline cortisol of
490  24 nmol/L and stimulated cortisol of 930  43 nmol/L. Whereas,
the second group (n ¼ 15 patients), those in poor physical condition, had
a much higher baseline cortisol of 1044  132 nmol/L and stimulated
cortisol of 1339  117 nmol/L.
Ross et al [33] performed a prospective study on patients with lung
cancer that was either non-small cell lung cancer (NSCLC) at stage 3 or 4
or small cell lung cancer (SCLC) at advanced stage. It is unclear if adrenal
metastases were present or not but it was not part of their inclusion
criteria. Adrenal function was assessed with baseline cortisol and an
ACTH stimulation test which required a 30 minute cortisol to be > 550
nmol/L. In their two groups of NSCLC and SCLC, they noted median
baseline cortisol was 432 nmol/L for NSCLC and 212 nmol/L for SCLC.
The median peak cortisol at 30 minutes for both groups combined was
828.5 nmol/L. Interestingly, they noted two patients with a stimulated
cortisol less than their 550 nmol/L criteria (536 nmol/L and 545 nmol/L,
respectively) which was thought to be consistent with AI. However,
because no documentation of deﬁnite adrenal involvement could be
gleaned from the study results, these could not be included in our
calculations.

bilateral adrenal metastases yet maintained normal adrenal function.
When assessed histologically, the residual normal functioning adrenal
tissue amounted to <20% of the total adrenal gland demonstrating the
remarkable ability of the adrenal glands to maintain adrenal function
with minimal functioning tissue.
Seidenwurm et al [29] in 1984 reported a case series of 6000
computed tomography (CT) scans, 949 autopsy reports (over period
1980–1981) and all endocrine referrals from 1964-1981. Patients had
unilateral or bilateral adrenal metastases conﬁrmed by biopsy or by CT.
There were 21 CT scans, 35 autopsies and one endocrine referral with
bilateral adrenal metastases (total n ¼ 57). Criteria for diagnosis of AI
was presence of two of the following: symptoms, signs or typical
biochemistry suggestive of AI, low cortisol or poor response to ACTH test
(deﬁned as failure to increase cortisol above 551 nmol/L 1 hour after
250mcg of ACTH) or a therapeutic response to steroids. Eight patients
met criteria for AI but three were excluded due to nephrectomy and only
two included ACTH in their diagnosis of AI. Thus for our initial prevalence calculations of AI: 2/57 (4%) and our subsequent calculations 5/57
(9%).
Redman et al [30] in 1987 collected 15 consecutive patients with
bilateral adrenal metastases conﬁrmed on CT scan and performed baseline cortisol and ACTH stimulation tests on them. Of these 15 patients, 10
had lung cancer. AI was deﬁned as failure to increase cortisol by 138
nmol/L above baseline or failure to have a stimulated cortisol >413
nmol/L. Five patients did not achieve this and were diagnosed with AI
giving a prevalence of 5/15 (33%).
Lutz et al [31] performed a cross sectional study of 28 patients
including controls and patients with either cancer, unilateral metastases
or bilateral metastases. No patients had AI. It has been described in
further detail below.
Two additional studies were added to expand the sample size [13,
32]. Lam et al [32] in 2002 performed an observational study of medical
records over a 30 year period involving 229 patients (49% of their total
number 464) with bilateral metastases conﬁrmed on histology (via autopsy, ﬁne needle aspiration (FNA) or adrenalectomy). Criteria for
diagnosis of AI was signs, symptoms or biochemical evidence of AI,
though whether an ACTH stimulation test was performed is not clear.
Five patients met this criteria, however, one had pituitary involvement as
well as adrenal involvement so was excluded. This left 4/229 patients
with AI (2%).
Delivanis et al [13] in 2016 retrospectively analysed the medical
records of 419 adrenal biopsies from 1994-2014 including clinical data,
imaging and surgical management. Eighty-two patients had bilateral
adrenal masses proven on imaging and of these, 50 were due to metastatic disease. Two of the 50 patients had primary adrenal insufﬁciency,
though the diagnostic criteria for the AI is not clear. This gives a prevalence of 2/50 (4%).
3.2. Secondary outcomes
3.2.1. Cortisol levels in patients with adrenal metastases with and without AI
The collected individual cases of AI with bilateral adrenal metastases
from Table 1 were used to evaluate basal cortisol and stimulated cortisol.
The systematic review also yielded ﬁve studies which commented on
adrenal function in patients with and without AI (three studies already
included in the review and two studies that did not meet inclusion
criteria). These have been summarised in Table 4 and below.
From our individual cases of AI (Table 1), the mean basal cortisol was
318  237 nmol/L and the mean stimulated cortisol was 423  238
nmol/L. The distribution of cortisol values have been plotted in Figs. 2
and 3 with a dashed line to demonstrated the number of cases with a
basal cortisol over 140 nmol/L or a stimulated cortisol over 500 nmol/L.
When Redman et al [30] performed their study on 15 patients with
bilateral metastases, we noted that the ﬁve patients with AI had baseline
cortisol levels between 303 nmol/L and 717 nmol/L, higher than the
criteria of <140 nmol/L. This study also compared the mean baseline

3.2.2. Other secondary outcomes
Basal ACTH levels in the collected cases of AI revealed median ACTH
concentration of 59 pmol/L (IQR 31–114). In terms of clinical features,
11/16 (68.8%) were hypotensive, 13/14 (9.3%) were hyponatremic and
12/12 (100%) were hyperkalemic. Lung cancer was the most common
malignancy reported to cause AI with 35% (7/20) of cases due to lung
cancer. This was followed by colorectal 20% (4/20), breast cancer 15%
(3/20) and lymphoma 10% (2/20).
The size of the adrenal metastases was 5.5  2.8 cm (left) and 5.5 
3.1 cm (right), respectively. The total size of the largest diameter of both
4
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Table 2
Quality assessment of prevalence studies included.
Author

Year

Type of Study

Strength

Limitations

Cedermark et al.
[28]

1981

Retrospective observational
study

 Small sample size with 7 consecutive patients, 3 with bilateral adrenal
metastases.

Seidenwurm
et al. [29]

1984

Retrospective observational
study

Redman et al.
[30]

1987

Prospective observational
study with intervention arm

Lutz et al. [31]

2000

Cross sectional observation
study.

Lam et al. [32]

2002

Retrospective observational
study

Delivanis et al.
[13]

2016

Retrospective observational
study

 Histology proven adrenal metastases
 Use of ACTH stimulation test for
diagnosis with clear documentation of
values.
 Representative of patients with
bilateral metastases
 Moderate sample size
 Clear documentation of bilateral
disease via CT or autopsy
 Representative of patients with
bilateral metastases
 Excluded treatment induced AI
 Used ACTH stimulation test for
diagnosis with clear documentation of
values
 Clear documentation of bilateral
disease
 Representative of patients with
bilateral metastases
 Clear documentation of bilateral
adrenal disease
 Exclude patients with prior treatment
that could affect adrenal function.
 Used ACTH stimulation testing
 Representative of patients with
bilateral disease
 Large sample size
 Clear documentation of bilateral
disease via autopsy, adrenalectomy or
FNA
 Population representative of patients
with bilateral metastases
 Moderate sample size with bilateral
disease
 Conﬁrmed radiological evidence of
bilateral disease
 Representative of population of
interest

 Used symptoms, signs or biochemistry suggestive of AI, as well as response
to glucocorticoids as part of diagnostic criteria rather than ACTH-stimulation
testing (only 2 patients had documented inappropriate response to ACTH
testing out of those included as AI)
 May have included patients with nephrectomy/adrenalectomy
 Small sample size

 Small sample size
 Diagnostic criteria for subclinical AI not validated (use of ACTH:cortisol
ratio)

 Inconsistent use of ACTH stimulation test for diagnosis
 Authors did not disclose the values for diagnosis of AI
 Diagnosed AI by using signs, symptoms and biochemical evidence with
unclear documentation of what this entails.

 No ACTH stimulation testing, used low cortisol and high ACTH levels to
diagnosis AI

AI ¼ adrenal insufﬁciency, ACTH ¼ adrenocorticotropin hormone, CT ¼ computer tomography, FNA ¼ ﬁne needle aspiration.

the left and right adrenal metastases was 11.0  5.6 cm. There was no
correlation between basal or stimulated cortisol concentration and the
size of adrenal metastases (r ¼ -0.298, P ¼ 0.323 and r ¼ -0.465, P ¼
0.207, respectively) nor ACTH concentrations and the size of adrenal
metastases (r ¼ 0.0622, P ¼ 0.921).
Of those with documented treatment (80% of cases), 70% (14/20)
used glucocorticoids alone and 30% (6/20) used a combination of glucocorticoids and mineralocorticoids. In those cases where mortality had
been noted, the median time to death was 5.0 months (IQR 0.6–6.5).
However, there were two cases being alive 12 months after diagnosis.

consistent with recommended diagnostic criteria, the stimulated cortisol
level is more helpful in distinguishing AI from non-AI patients as seen in
Fig. 3 and the study by Redman et al [30].
This review yielded data supporting the ability of the adrenal gland to
maintain function until most of the gland is destroyed (>90%) [28], an
important concept to remember when faced with large bilateral adrenal
metastases on radiology. We also had data on the adrenal gland function
Table 3
Studies of prevalence of adrenal insufﬁciency in patients with bilateral adrenal
metastases.

4. Discussion

Prevalence of AI as documented by ACTH stimulation test
Cedermark et al [28]
1981
0/4 (0%)
Seidenwurm et al [29]
1984
2/57 (3.5%)
Redman et al [30],*
1987
5/15 (33.3%)
Lutz et al [31],**
2000
0/9 (0%)
Total prevalence of AI
Total prevalence of AI excluding Redman et al [30],*

This is the ﬁrst systematic review summarising data on AI in patients
with bilateral adrenal metastases. We provide data on prevalence, etiology, clinical features, diagnosis and mortality.
The prevalence of primary AI in bilateral adrenal metastases (ideally
diagnosed with ACTH stimulation testing) was 3–8% or 6.1% if allowing
for more lax diagnostic criteria (as per secondary calculations). This
systematic review demonstrated the paucity of good quality studies on
the topic and a need for further research with consistent diagnostic
criteria of AI in the setting of bilateral adrenal metastases. This is
important when reﬂecting on our prevalence calculations.
Despite the limited number of studies included, there is valuable information to be gleaned regarding adrenal function in malignancy. First
of all, basal cortisol levels in cases of AI demonstrate that majority of
cases are much higher than 140 nmol/L and supports its unreliability as a
screening tool for patients with malignancy. This is likely due to the
"stressed" adrenal response that results from advanced malignancy. As

7/85 (8.2%)
2/70 (2.9%)

Prevalence of AI as documented by either ACTH stimulation test or clinical criteria
Cedermark et al [28]
Seidenwurm et al [29]
Redman et al [30],*
Lutz et al [31],**
Lam et al [32]
Delivanis et al [13]
Total prevalence of AI
*

1981
1984
1987
2000
2002
2016

0/4 (0%)
5/57 (8.7%)
5/15 (33.3%)
0/9 (0%)
4/229 (1.74%)
2/50 (4%)
16/264 (6.1%)

All cases had a basal cortisol level of >300 nmol/L but failed mount an
appropriate response to ACTH stimulation.
**
Lutz et al - study only contained subjects with subclinical AI rather than
overt AI.
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Fig. 1. Flow diagram of process of systematic review.

pointed out that lung malignancies may release an ACTH-like substance
and the fact that many of the cases of AI in this review were due to lung
cancer, ACTH may not be optimal as a screening tool for AI.
This systematic review and meta-analysis provides information on
clinical features of AI in the cohort of patients with bilateral adrenal
metastases. It was common to see the classic clinical and biochemical
features of hypotension, hyponatremia and hyperkalemia, however,
majority of these were from case reports where patients presented with
overt adrenal failure. A number of studies [9, 29, 30, 31, 33] commented
that patients not meeting criteria for AI had symptoms and signs of AI
suggesting its lack of utility and signiﬁcance in metastatic malignancy.
In regards to size of adrenal metastases on radiology, there was large
variation and no meaningful information can be gleaned from the small
number of cases, and there were no signiﬁcant correlations between
cortisol nor ACTH concentrations and the total size of the adrenal metastases. Further studies with comparison of size between AI and non-AI
patients with bilateral metastases is required.
There has been a paucity of detailed data on treatment and survival
for patients with AI in malignancy. Along with overlap of clinical signs,
there is treatment overlap between the two conditions. Many patients
with malignancies are treated with glucocorticoids to alleviate nausea
from chemotherapy, reduced cerebral oedema and for its

as malignancy progressed from focal disease to metastatic to involving
one or both adrenal glands. There was a consistent rise in basal and
stimulated cortisol levels for each step in the progression of malignancy,
which may or may not be relevant when it comes to performing the ACTH
stimulation test in each patient group. Even the functional performance
of a patient (i.e. ECOG status) reﬂects the underlying "stress" on the
adrenal system [9]. On the other hand, severe weight loss can reduce
plasma corticosteroid binding globulin, which if not met by an increase in
cortisol secretion may lower measured total plasma cortisol [34]. How
the ACTH stimulation test performs as a screening and diagnostic tool in
patients with AI due to adrenal metastases compared to AI due to other
causes is unclear but should be investigated in future studies.
Screening all patients with bilateral adrenal metastases for AI with
ACTH stimulation testing is possible, although the cost-beneﬁt of this
approach has not been evaluated, especially as the presence of AI can be
excluded clinically in some patients, e.g., in those with hypertension, and
the detection of mild AI may not inﬂuence prognosis. However, symptoms
attributed to advanced malignancy or cancer therapy may be the unrecognised presentation of AI and a clinical assessment in patients with bilateral metastases with selected ACTH stimulation testing seems reasonable.
Minimal focus has been played on use of ACTH in assisting diagnosis
of AI in the setting of malignancy. However, as Cedermark et al [9]
6
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Table 4
Summary of adrenal function in patients without AI in malignancy.
Controls

Cancer, no metastases

U/L adrenal
metastasis

B/L adrenal metastases
but no AI

Disseminated
malignancy

AI

477.5  64.9 nmol/L

440.4  53.5
nmol/L
-

637.6  92.1 nmol/L

-

-

Redman et al [30]
Cedermark et al [9]

307.4  33.2
nmol/L
-

582 nmol/L
-

-

656 nmol/L
-

Cedermark et al [28]
Ross et al [33]

-

-

862.5 nmol/L
-

-

Baseline Cortisol
Lutz et al [31]

490  24 nmol/L (well
patients)
1044  132 nmol/L
-

Individual cases of AI
from Table 1
Stimulated cortisol or increase in cortisol
Lutz et al [31]
794.6  41.2
nmol/L
Redman et al [30]
-

-

-

-

NSCLC 432 nmol/L
SCLC 212 nmol/L
-

939.7  99.2 nmol/L

990.8  92.9
nmol/L
-

1151.4  155.5 nmol/L

-

-

-

Cedermark et al [9]

-

-

-

35 nmol/L (increase
from baseline)
-

Cedermark et al [28]

-

930  43 nmol/L (well
patients)
1339  117 nmol/L
(unwell patients)
-

480 nmol/L (increase
from baseline)
-

-

-

Ross et al [33]

-

-

-

1137.5 nmol/L (mean
stimulated cortisol)
225 nmol/L (mean
increase from baseline)
-

-

Individual cases of AI
from Table 1

-

-

-

-

828.5 (536–1675) nmol/L
(median for both groups)
-

-

-

318  237 nmol/L

423  238 nmol/L

U/L ¼ unilateral; B/L ¼ bilateral; NSCLC ¼ non-small cell lung cancer; SCLC ¼ small cell lung cancer.

being the small number of studies meeting inclusion criteria for prevalence calculations as well as the small number of individual cases. Majority of the original research articles were published over 20 years ago.
Even though an ACTH stimulation test was required for inclusion, the
cortisol levels for diagnosis varied between studies. Moreover, majority
of studies were retrospective observational studies and the inherent
limitations of all retrospective studies, in particular that of ascertainment
bias, were also present in this systematic review. Selection bias may have
driven those tested for cortisol levels, especially when performed on
unstimulated samples, leading to overestimation of AI prevalence.
Most case reports were in overt adrenal failure with obvious clinical
signs and biochemical features (most had the classic hyponatremia and
hyperkalemia with hypotension), which may reduce the generalization
to a broader population of patients with bilateral adrenal metastases. A
lack of reporting of detailed clinical features, in particular survival
duration, of the identiﬁed cases limited clinical analyses.
A comprehensive study of this area would involve detection of adrenal metastases on routine abdominal imaging, followed by prospective
assessment for symptoms of AI, an ACTH-stimulation test documenting
values for those with AI and without AI, baseline ACTH, measures of
aldosterone and renin, followed by an assessment of response to treatment after two weeks of hormone replacement and longer term follow up
of survival between the two groups.

Fig. 2. Basal cortisol concentrations (nmol/L) for individual cases of adrenal
insufﬁciency due to bilateral adrenal metastases.

lymphocytolytic effects [35]. Thus, a clinical response to treatment with
glucocorticoids is not speciﬁc to AI. However, in those cases included
with documented follow-up the prognosis was very poor.
This systematic review and meta-analysis had limitations, the largest

5. Conclusion
Adrenal insufﬁciency, variously deﬁned by different studies, occurs in
approximately 3–8% of individuals with bilateral adrenal metastases. AI
was most commonly seen in bilateral adrenal metastases from lung
cancers. The effects of malignancy on cortisol levels was notable for
increasing stages of metastasis and its effect on interpretation and utility
of the ACTH stimulation test is unknown. Of note, baseline cortisol,
ACTH, clinical signs or symptoms of AI or response to steroids play
limited role in diagnosis or screening for AI in patients with bilateral
adrenal metastases. Physicians should have an increased awareness of

Fig. 3. Stimulated cortisol concentrations (nmol/L) for individual cases of adrenal insufﬁciency due to bilateral adrenal metastases.
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the possibility of AI in malignancy and rely on ACTH stimulation testing
for diagnosis. Further studies of patients with bilateral adrenal metastases with and without AI are required.
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